期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
“Treat-all”Strategy for Patients with Chronic Hepatitis B Virus Infection in China:Are We There Yet? 被引量:1
1
作者 Mengyang Zhang Yuanyuan Kong +3 位作者 Xiaoqian Xu Yameng Sun Jidong Jia Hong You 《Journal of Clinical and Translational Hepatology》 SCIE 2024年第6期589-593,共5页
Chronic hepatitis B remains the primary cause of liver-related events in China.The World Health Organization set a goal to eliminate viral hepatitis as a public health threat by 2030.However,achieving this goal appear... Chronic hepatitis B remains the primary cause of liver-related events in China.The World Health Organization set a goal to eliminate viral hepatitis as a public health threat by 2030.However,achieving this goal appears challenging due to the current low rates of diagnosis and treatment.The“Treat-all”strategy,which proposes treating all patients with detectable hepatitis B virus(HBV)DNA or even all patients with positive HBsAg,has been suggested to simplify anti-HBV treatment.In 2022,the Chinese Society of Hepatology and the Chinese Society of Infectious Diseases updated the guidelines for the prevention and treatment of chronic hepatitis B in China,expanding antiviral indications and simplifying the treatment algorithm.According to this latest guideline,nearly 95%of patients with detectable HBV DNA are eligible for antiviral treatment.This review aimed to provide a detailed interpretation of the treatment indications outlined in the Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis B(version 2022)and to identify gaps in achieving the“Treat-all”strategy in China. 展开更多
关键词 Chronic hepatitis B Antiviral therapy treatment indication expanding treatment treatment rate “Treat-all”strategy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部